Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung

• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2• Approval of Giotrif® is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung3• Afatinib is already approved in more than 60 countries for the treatment of patients with EGFR mutation-positive NSCLC*
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news